Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 4291-4300 Newer>

The Motley Fool October 31, 2007 Brian Lawler	The Next Hepatitis C Blockbuster? Never before have there been so many new drugs in development to treat Hepatitis C. Which companies have the compounds most likely to win this race? Investors, take note.
The Motley Fool October 31, 2007 Brian Lawler	Depomed Plays Hot Potato Following disappointing sales numbers, King Pharmaceuticals and Depomed terminate their marketing collaboration deal.
The Motley Fool October 31, 2007 Brian Orelli	From Apples to Apple Pie at Teva Year-over-year sales skyrocket at Teva Pharmaceutical, due to the launch of more than 25 new products. Investors, take note.
The Motley Fool October 31, 2007 Brian Lawler	Sanofi: Stable, for Now The drugmaker's healthy Q3 results shine amid slumping competitors. Investors, take note.
The Motley Fool October 31, 2007 Brian Lawler	Alpharma's Loading Up Animal health division sales may have decreased, but the specialty drug developer is expecting renewed growth in its pharmaceutical division.
The Motley Fool October 31, 2007 Brian Lawler	Nastech Still Breathing Coming phase 2 results on four different compounds will help investors assess how well Nastech's nasally-administered drugs might sell. Investors, take note.
The Motley Fool October 30, 2007 Brian Orelli	Big Pharma's Takeover Wish List Which companies may be the next big pharma buyout candidates? Investors, take note.
The Motley Fool October 30, 2007 Billy Fisher	5 Top Health-Care and Biotech Stocks These five stocks in the health-care and biotech sectors are poised for growth; investors, take a look at: LifeCell... American Oriental Bioengineering... ArthroCare... Hologic... Healthways...
The Motley Fool October 30, 2007 Brian Orelli	Laurels, Shmaurels, Let's Grow Ultrasound maker SonoSite produces another impressive quarter; management states there's plenty of room to grow and cash to spend. Investors, take note.
The Motley Fool October 30, 2007 Brian Lawler	ViroPharma Gets No Respect The drugmaker announces third-quarter results; sales of its only marketed drug, antibiotic treatment Vancocin, fell due to a higher level of wholesaler stocking. Investors, take note.
<Older 4291-4300 Newer> Return to current articles.